drugset

drugset / Trial / NCT03667820

Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLC

NCT03667820 ↗

Phase 2 Active not recruiting 41 enrolled University of Texas Southwestern Medical Center AstraZeneca · collab

NaSingle-groupOpen-labelTreatment

Summary

This study evaluates the combination of two well-tolerated therapies, osimertinib and Stereotactic Ablative Radiation (SABR).

Timeline

Start: 2018-09-26
Primary completion: 2027-09-30
Completion: 2027-09-30

Publications

Sampath S, Rashdan S, Iyengar P, Mickel TA, Zhang S, Ahn C, Gao A, Dowell JE, Zhang Y, Westover KD, Cole SM, Amini A, Rock A, Massarelli E, Koczywas M, Gerber DE. Osimertinib plus consolidative radiotherapy for advanced EGFR mutant non-small cell lung cancer: a multicentre, single-arm, phase 2 trial. EClinicalMedicine. 2025 Aug 26;87:103435. doi: 10.1016/j.eclinm.2025.103435. eCollection 2025 Sep.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Osimertinib	Small molecule	80 mg	Oral

Indications